Cargando…

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

BACKGROUND: Diabetes is one of the most prevalent chronic diseases, and its prevalence is predicted to increase in the next two decades. Diabetes imposes a staggering financial burden on the health care system, so information about the costs and experiences of collecting and reporting quality measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposti, Luca Degli, Saragoni, Stefania, Buda, Stefano, Sturani, Alessandra, Esposti, Ezio Degli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658432/
https://www.ncbi.nlm.nih.gov/pubmed/23696709
http://dx.doi.org/10.2147/CEOR.S41846
_version_ 1782270273837334528
author Esposti, Luca Degli
Saragoni, Stefania
Buda, Stefano
Sturani, Alessandra
Esposti, Ezio Degli
author_facet Esposti, Luca Degli
Saragoni, Stefania
Buda, Stefano
Sturani, Alessandra
Esposti, Ezio Degli
author_sort Esposti, Luca Degli
collection PubMed
description BACKGROUND: Diabetes is one of the most prevalent chronic diseases, and its prevalence is predicted to increase in the next two decades. Diabetes imposes a staggering financial burden on the health care system, so information about the costs and experiences of collecting and reporting quality measures of data is vital for practices deciding whether to adopt quality improvements or monitor existing initiatives. The aim of this study was to quantify the association between health care costs and level of glycemic control in patients with type 2 diabetes using clinical and administrative databases. METHODS: A retrospective analysis using a large administrative database and a clinical registry containing laboratory results was performed. Patients were subdivided according to their glycated hemoglobin level. Multivariate analyses were used to control for differences in potential confounding factors, including age, gender, Charlson comorbidity index, presence of dyslipidemia, hypertension, or cardiovascular disease, and degree of adherence with antidiabetic drugs among the study groups. RESULTS: Of the total population of 700,000 subjects, 31,022 were identified as being diabetic (4.4% of the entire population). Of these, 21,586 met the study inclusion criteria. In total, 31.5% of patients had very poor glycemic control and 25.7% had excellent control. Over 2 years, the mean diabetes-related cost per person was: €1291.56 in patients with excellent control; €1545.99 in those with good control; €1584.07 in those with fair control; €1839.42 in those with poor control; and €1894.80 in those with very poor control. After adjustment, compared with the group having excellent control, the estimated excess cost per person associated with the groups with good control, fair control, poor control, and very poor control was €219.28, €264.65, €513.18, and €564.79, respectively. CONCLUSION: Many patients showed suboptimal glycemic control. Lower levels of glycated hemoglobin were associated with lower diabetes-related health care costs. Integration of administrative databases and a laboratory database appears to be suitable for showing that appropriate management of diabetes can help to achieve better resource allocation.
format Online
Article
Text
id pubmed-3658432
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36584322013-05-21 Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases Esposti, Luca Degli Saragoni, Stefania Buda, Stefano Sturani, Alessandra Esposti, Ezio Degli Clinicoecon Outcomes Res Original Research BACKGROUND: Diabetes is one of the most prevalent chronic diseases, and its prevalence is predicted to increase in the next two decades. Diabetes imposes a staggering financial burden on the health care system, so information about the costs and experiences of collecting and reporting quality measures of data is vital for practices deciding whether to adopt quality improvements or monitor existing initiatives. The aim of this study was to quantify the association between health care costs and level of glycemic control in patients with type 2 diabetes using clinical and administrative databases. METHODS: A retrospective analysis using a large administrative database and a clinical registry containing laboratory results was performed. Patients were subdivided according to their glycated hemoglobin level. Multivariate analyses were used to control for differences in potential confounding factors, including age, gender, Charlson comorbidity index, presence of dyslipidemia, hypertension, or cardiovascular disease, and degree of adherence with antidiabetic drugs among the study groups. RESULTS: Of the total population of 700,000 subjects, 31,022 were identified as being diabetic (4.4% of the entire population). Of these, 21,586 met the study inclusion criteria. In total, 31.5% of patients had very poor glycemic control and 25.7% had excellent control. Over 2 years, the mean diabetes-related cost per person was: €1291.56 in patients with excellent control; €1545.99 in those with good control; €1584.07 in those with fair control; €1839.42 in those with poor control; and €1894.80 in those with very poor control. After adjustment, compared with the group having excellent control, the estimated excess cost per person associated with the groups with good control, fair control, poor control, and very poor control was €219.28, €264.65, €513.18, and €564.79, respectively. CONCLUSION: Many patients showed suboptimal glycemic control. Lower levels of glycated hemoglobin were associated with lower diabetes-related health care costs. Integration of administrative databases and a laboratory database appears to be suitable for showing that appropriate management of diabetes can help to achieve better resource allocation. Dove Medical Press 2013-05-14 /pmc/articles/PMC3658432/ /pubmed/23696709 http://dx.doi.org/10.2147/CEOR.S41846 Text en © 2013 Degli Esposti et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Esposti, Luca Degli
Saragoni, Stefania
Buda, Stefano
Sturani, Alessandra
Esposti, Ezio Degli
Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title_full Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title_fullStr Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title_full_unstemmed Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title_short Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
title_sort glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658432/
https://www.ncbi.nlm.nih.gov/pubmed/23696709
http://dx.doi.org/10.2147/CEOR.S41846
work_keys_str_mv AT espostilucadegli glycemiccontrolanddiabetesrelatedhealthcarecostsintype2diabetesretrospectiveanalysisbasedonclinicalandadministrativedatabases
AT saragonistefania glycemiccontrolanddiabetesrelatedhealthcarecostsintype2diabetesretrospectiveanalysisbasedonclinicalandadministrativedatabases
AT budastefano glycemiccontrolanddiabetesrelatedhealthcarecostsintype2diabetesretrospectiveanalysisbasedonclinicalandadministrativedatabases
AT sturanialessandra glycemiccontrolanddiabetesrelatedhealthcarecostsintype2diabetesretrospectiveanalysisbasedonclinicalandadministrativedatabases
AT espostieziodegli glycemiccontrolanddiabetesrelatedhealthcarecostsintype2diabetesretrospectiveanalysisbasedonclinicalandadministrativedatabases